- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04469075
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
April 19, 2024 updated by: Memorial Sloan Kettering Cancer Center
The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields
The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects.
This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
58
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alina Markova, MD
- Phone Number: 646-608-2342
- Email: markovaa@mskcc.org
Study Contact Backup
- Name: Rashek Kazi, MD,PhD
- Email: kazir@mskcc.org
Study Locations
-
-
Illinois
-
Evanston, Illinois, United States, 60208
- Recruiting
- Northwestern University
-
Contact:
- Priya Kumthekar, MD
- Email: p-kumthekar@northwestern.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Active, not recruiting
- Tufts Medical Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Active, not recruiting
- Washington University School of Medicine
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Recruiting
- Hackensack Meridian Health
-
Contact:
- Deric M Park, MD, FACP
- Phone Number: 844-301-4158
-
-
New York
-
Hauppauge, New York, United States, 11788
- Recruiting
- Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities)
-
Contact:
- Alina Markova, MD
- Phone Number: 646-608-2342
-
New York, New York, United States, 10021
- Recruiting
- Memorial Sloan Kettering Cancer Center
-
Contact:
- Alina Markova, MD
- Phone Number: 646-608-2342
-
Principal Investigator:
- Alina Markova, MD
-
Contact:
- Rashek Kazi, MD, PhD
- Email: kazir@mskcc.org
-
New York, New York, United States, 10032
- Active, not recruiting
- Columbia University
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Active, not recruiting
- University of Cincinnati Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age ≥18 years
- Diagnosis of newly diagnosed or recurrent GBM with plan to initiate treatment with TTFields with or without systemic therapy, confirmed by the enrolling institution
- Able to self-administer topical interventions or has available another person who can apply the topical agents
- Treatment with TTF should be initiated within 7 days of planned initiation on this trial.
Exclusion Criteria:
- Known history of allergy to any ingredient of the study agents
- Preexisting scalp disorders such as psoriasis or dermatitis that, in the opinion of the investigator, will affect the grading of skin adverse events, confirmed by enrolling institution.
- Use of concurrent topical therapy to the scalp for another dermatologic condition
- Active, uncontrolled infection requiring systemic or oral antibiotic therapy within 14 days of enrollment
- Use of greater than 4 mg dexamethasone a day within 14 days of enrollment
- Malignant glioma
- Pregnant Women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: topical clindamycin and triamcinolone
Patients who are scheduled to receive TTFields therapy for newly diagnosed GBM will be treated with: topical clindamycin (or approved equivalent) 1% and triamcinolone 0.1%.
Participating sites may use an alternative equivalent form of clindamycin, such as a gel, with MSK PI approval
|
phosphate 1% solution triamcinolone 0.01% at every array change (or approved equivalent)
triamcinolone acetonide 0.01% lotion triamcinolone 0.01% at every array change
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients without grade 2 or higher skin toxicity
Time Frame: up to 120 days
|
device-related skin adverse events by investigator assessment.
|
up to 120 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
skin-related quality of life
Time Frame: up to 120 days
|
using the PRO-CTCAE for rash, ulcer, and pruritus.
|
up to 120 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Alina Markova, MD, Memorial Sloan Kettering Cancer Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 9, 2020
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
July 1, 2025
Study Registration Dates
First Submitted
July 10, 2020
First Submitted That Met QC Criteria
July 10, 2020
First Posted (Actual)
July 13, 2020
Study Record Updates
Last Update Posted (Estimated)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 19, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioblastoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Triamcinolone
- Clindamycin
- Clindamycin palmitate
- Clindamycin phosphate
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
Other Study ID Numbers
- 19-342
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials.
The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov
when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required.
Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication.
Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals.
Requests may be made to: crdatashare@mskcc.org.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on Clindamycin Phosphate
-
Taro Pharmaceuticals USACompletedAcne VulgarisUnited States
-
Lumara Health, Inc.CompletedVaginitis | VulvovaginitisUnited States, Russian Federation, Puerto Rico, India
-
Phillip Brian SmithEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedSafety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile (CLIN01)Obesity | Bacterial InfectionsUnited States
-
Actavis Inc.Watson Laboratories, Inc.CompletedBACTERIAL VAGINOSIS | Signs and Symptoms to be Evaluated and Recorded Include | Vaginal Discharge Color, Odor, and Consistency | Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe | Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or SevereUnited States, Dominican Republic, Puerto Rico
-
Skaraborg HospitalCompleted
-
Watson Laboratories, Inc.Completed
-
Gage Development Company, LLCCompletedAcne VulgarisUnited States
-
Lumara Health, Inc.Completed
-
GlaxoSmithKlineCompleted
-
Wake Forest UniversityMedicis Pharmaceutical CorporationCompleted